BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 28260718)

  • 1. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
    Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
    Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer.
    Zhou X; Sekino Y; Li HT; Fu G; Yang Z; Zhao S; Gujar H; Zu X; Weisenberger DJ; Gill IS; Tulpule V; D'souza A; Quinn DI; Han B; Liang G
    Cancer Res; 2023 Nov; 83(22):3813-3826. PubMed ID: 37695044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
    Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
    Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A missense SNP in the tumor suppressor SETD2 reduces H3K36me3 and mitotic spindle integrity in Drosophila.
    Brockett JS; Manalo T; Zein-Sabatto H; Lee J; Fang J; Chu P; Feng H; Patil D; Davidson P; Ogan K; Master VA; Pattaras JG; Roberts DL; Bergquist SH; Reyna MA; Petros JA; Lerit DA; Arnold RS
    Genetics; 2024 Apr; 226(4):. PubMed ID: 38290049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SETDB2 and RIOX2 are differentially expressed among renal cell tumor subtypes, associating with prognosis and metastization.
    Ferreira MJ; Pires-Luís AS; Vieira-Coimbra M; Costa-Pinheiro P; Antunes L; Dias PC; Lobo F; Oliveira J; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
    Epigenetics; 2017; 12(12):1057-1064. PubMed ID: 29099276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinformatic Analysis and Clinical Case Studies Identify CD276 as a Promising Diagnostic Biomarker for Clear Cell Renal Cell Carcinoma.
    Zhang Z; Xu J; Song Z; Zhang J; Lin Y; Ouyang J
    Cancer Control; 2024; 31():10732748241250181. PubMed ID: 38669187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining UBR5 and CD163
    Wang C; Hong T; Wang Y; Peng G; Yu Y; Zhang J; Zhuo D; Zheng J; Ma X; Cui X
    Cancer Immunol Immunother; 2021 Oct; 70(10):2925-2935. PubMed ID: 33710368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma.
    Chakiryan NH; Hajiran A; Kim Y; Aydin AM; Zemp L; Katende E; Nguyen J; Fan W; Cheng CH; Lopez-Blanco N; Chahoud J; Spiess PE; Fournier M; Dhillon J; Wang L; Moran-Segura C; Mulé J; Du D; Yoder SJ; Berglund A; Teer JK; Manley BJ
    Eur Urol Focus; 2022 May; 8(3):784-793. PubMed ID: 33994165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation.
    Javaid H; Barberis A; Chervova O; Nassiri I; Voloshin V; Sato Y; Ogawa S; Fairfax B; Buffa F; Humphrey TC
    BMC Cancer; 2023 Aug; 23(1):721. PubMed ID: 37528416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioinformatics analysis identifies GLUD1 as a prognostic indicator for clear cell renal cell carcinoma.
    Liu S
    Eur J Med Res; 2024 Jan; 29(1):70. PubMed ID: 38245763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological Significance of Kidney and Brain Expressed Protein (KIBRA) in Clear Cell Renal Cell Carcinoma.
    Nagashima Y; Mitsunari K; Matsuo T; Nakamura Y; Miyata Y; Ohba K
    Anticancer Res; 2023 Jan; 43(1):45-51. PubMed ID: 36585159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT-Based Radiogenomics of P4HA3 Expression in Clear Cell Renal Cell Carcinoma.
    Greco F; Panunzio A; Tafuri A; Bernetti C; Pagliarulo V; Zobel BB; Scardapane A; Mallio CA
    Acad Radiol; 2024 Mar; 31(3):902-908. PubMed ID: 37537130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenic Roles for RNASET2 in Clear Cell Renal Cell Carcinoma.
    Peak T; Tian Y; Patel A; Shaw T; Obermayer A; Laborde J; Kim Y; Johnson J; Stewart P; Fang B; Teer JK; Koomen J; Berglund A; Marchion D; Francis N; Echevarria PR; Dhillon J; Clark N; Chang A; Sexton W; Zemp L; Chahoud J; Wang L; Manley B
    Lab Invest; 2024 May; 104(5):102041. PubMed ID: 38431116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysine methyltransferase 5C increases the proliferation and metastatic abilities of clear cell renal cell carcinoma via aerobic glycolysis.
    Zeng B; Wan R; Chang K; Li J; Zhang X; Shi G; Ye D; Xu F
    Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38426605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive molecular characterization of clear cell renal cell carcinoma.
    Cancer Genome Atlas Research Network
    Nature; 2013 Jul; 499(7456):43-9. PubMed ID: 23792563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.
    Liu XD; Zhang YT; McGrail DJ; Zhang X; Lam T; Hoang A; Hasanov E; Manyam G; Peterson CB; Zhu H; Kumar SV; Akbani R; Pilie PG; Tannir NM; Peng G; Jonasch E
    Clin Cancer Res; 2023 Oct; 29(19):4002-4015. PubMed ID: 37527013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paternal high-fat diet altered H3K36me3 pattern of pre-implantation embryos.
    Meng B; He J; Cao W; Zhang Y; Qi J; Luo S; Shen C; Zhao J; Xue Y; Qu P; Liu E
    Zygote; 2024 Feb; 32(1):1-6. PubMed ID: 38018398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatiotemporal role of SETD2-H3K36me3 in murine pancreatic organogenesis.
    Lu P; Xu J; Shen X; Sun J; Liu M; Niu N; Wang Q; Xue J
    Cell Rep; 2024 Feb; 43(2):113703. PubMed ID: 38265933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SETD2 maintains nuclear lamina stability to safeguard the genome.
    Khan A; Metts JM; Collins LC; Mills CA; Li K; Brademeyer AL; Bowman BM; Major MB; Aubé J; Herring LE; Davis IJ; Strahl BD
    bioRxiv; 2023 Sep; ():. PubMed ID: 37808753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Setd2 deficiency promotes gastric tumorigenesis through inhibiting the SIRT1/FOXO pathway.
    Feng W; Ma C; Rao H; Zhang W; Liu C; Xu Y; Aji R; Wang Z; Xu J; Gao WQ; Li L
    Cancer Lett; 2023 Nov; 579():216470. PubMed ID: 37914019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.